Abstract:e13663 Background: Cyclin-dependent kinase 12 (CDK12) is a cyclin-dependent kinase that regulates transcription and RNA splicing, thereby modulating multiple cellular processes. It has been suggested that CDK12 loss-of-function mutations lead to a higher neoantigen burden and favorable responses to PD-1 inhibitors in advanced prostate cancer. Given this potentially actionable molecular subtype, we sought to determine the prevalence of CDK12 alterations in Chinese cancer patients and the association with TMB and overall survival(OS). Methods: The prevalence of CDK12 alterations were queried in 3D Medicines database with 15,745 Chinese cancer patients involved. Whole-exome sequencing data of 464 patients with prostate adenocarcinoma(PRAD) from the Cancer Genome Altas (TCGA) were downloaded to explore the association between CDK12 gene alteration and OS. And the association with TMB were analyzed in a cohort of 731 patients with various cancer types published by Memorial Sloan Kettering (MSKCC) (Samstein et al., Nature Genetics, 2019). Results: Any CDK12 and known or likely deleterious CDK12 mutations were identified in 598(3.8%) and 98(0.62%) patients, respectively. Across all cancer types, prostate adenocarcinoma(PRAD) was found to have the highest frequency of deleterious mutations(8.75%, 23/263), followed by breast cancer (4.97%, 25/503). Mutations were also detected in multiple cancer types including bladder cancer, ovarian cancer, lung cancer, colorectal cancer and so on with a frequency of less than 1%. CDK12 mutations were associated with shorter OS (HR = 15.25; 95% CI, 2.88-80.73; p < 0.001) in TCGA PRAD and cholangiocarcinoma datasets, which was not seen in other cancer types. Patients harboring CDK12 mutation had a significant higher TMB(p < 0.001) in the pan-cancer study of publicly-available cohort from MSKCC. Conclusions: CDK12 alterations existed across tumor types in Chinese patients with relatively high frequencies detected in PRAD and breast cancer and represent extremely rare events in multiple cancers. CDK12 mutation was a poor prognostic factor in PRAD and cholangiocarcinoma. In a pan cancer analysis patients with CDK12 mutation tended to have a significant higher TMB and may benefit from PD-1/L1 blockade immunotherapy.

CDK12 Promotes Cervical Cancer Progression through Enhancing Macrophage Infiltration

CDK12 is a potential biomarker for diagnosis, prognosis and immunomodulation in pan-cancer

Cyclin-dependent Kinase 9 Promotes Cervical Cancer Development Via AKT2/p53 Pathway.

Development of CDK12 as a Cancer Therapeutic Target and Related Inhibitors

CDK12 Promotes the Proliferation, Migration, and Angiogenesis of Gastric Carcinoma via Activating the PI3K/AKT/mTOR Signaling Pathway

CDK1 promotes the phosphorylation of KIFC1 to regulate the tumorgenicity of endometrial carcinoma

CDK12: A Potent Target and Biomarker for Human Cancer Therapy

Comprehensive Gene and Pathway Analysis of Cervical Cancer Progression.

NCAPD2 promotes breast cancer progression through E2F1 transcriptional regulation of CDK1

CDK15 promotes colorectal cancer progression via phosphorylating PAK4 and regulating β-catenin/ MEK-ERK signaling pathway

CDK12 loss inhibits cell proliferation by regulating TBK1 in non-small cell lung cancer cells

The Prevalence of CDK12 Alterations in Chinese Cancer Patients and the Association with Tumor Mutation Burden(tmb) and Survival.

Original CKAP2 promotes cervical cancer progression by modulating the tumor microenvironment via NF-KB signaling

Targeting CDK12 Obviates the Malignant Phenotypes of Colorectal Cancer Through the Wnt/β-catenin Signaling Pathway

Critical Role of CDK11p58 in Human Breast Cancer Growth and Angiogenesis

CDK16 promotes the progression and metastasis of triple-negative breast cancer by phosphorylating PRC1

The role of NFATc1/c-myc/PKM2/IL-10 axis in activating cervical cancer tumor-associated M2 macrophage polarization to promote cervical cancer progression

KCTD12 promotes tumorigenesis by facilitating CDC25B/CDK1/Aurora A-dependent G2/M transition

[The Role of Tumor-Associated Macrophages in the Development and Progression of Cervical Cancer].

P12(Cdk2-Ap1) Inhibits Breast Cancer Cell Proliferation and in Vivo Tumor Growth

Cadherin-12 enhances proliferation in colorectal cancer cells and increases progression by promoting EMT